Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The role of natural interleukin-1 receptor antagonist in amyloid-induced Fas-mediated beta-cell death
EF 2015-16
Résumé
Type 2 diabetes (T2D) is characterized by impaired function and loss of insulin producing pancreatic ß-cells which leads to elevated blood glucose. Patients with T2D require life-long treatment to control their blood glucose levels. Islet inflammation caused by inflammatory proteins named cytokines such as interleukin-1ß (IL-1ß) play a key role in ß-cell loss in T2D. The body produces a natural inhibitor of IL-1ß called IL-1 receptor antagonist (IL-1Ra) to modulate IL-1ß action. IL-1Ra is reduced in patients with T2D suggesting an important role for IL-1Ra and IL-1Ra/IL-1ß ratio in the development of diabetes. The factors contributing to reduced IL-1Ra levels in T2D have yet to be identified. Islet amyloid deposits are protein aggregates formed by a small protein named islet amyloid polypeptide that is produced in the pancreatic ß-cells. Amyloid deposits are toxic to ß-cells and contribute to progressive ß-cell loss in T2D and transplanted islets in T1D patients. Growing evidence suggests that islet amyloid contributes to islet inflammation.In these studies, we will use pancreatic islets (cluster of cells containing ß-cells) from cadaveric human pancreatic donors and mouse models of human islet amyloid formation, to investigate the molecular mechanisms by which amyloid formation destroys ß-cells. We will use various molecular techniques to identify the role of IL-1Ra and IL-1ß signaling in amyloid-induced ß-cell toxicity. Through these studies, we hope to find new therapeutic approaches to preserve insulin producing ß-cells in patients with T2D and prolong survival of islet grafts in patients with T1D and thereby improve the lives of diabetic patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
349985
Name
Hui Queenie
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of natural interleukin-1 receptor antagonist in amyloid-induced Fas-mediated beta-cell death
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Il-1 Receptor Antagonist; Il-1í; Islet Amyloid; Islet Survival; Í-Cell Apoptosis; Í-Cell Function
Abstract
Type 2 diabetes (T2D) is characterized by impaired function and loss of insulin producing pancreatic ß-cells which leads to elevated blood glucose. Patients with T2D require life-long treatment to control their blood glucose levels. Islet inflammation caused by inflammatory proteins named cytokines such as interleukin-1ß (IL-1ß) play a key role in ß-cell loss in T2D. The body produces a natural inhibitor of IL-1ß called IL-1 receptor antagonist (IL-1Ra) to modulate IL-1ß action. IL-1Ra is reduced in patients with T2D suggesting an important role for IL-1Ra and IL-1Ra/IL-1ß ratio in the development of diabetes. The factors contributing to reduced IL-1Ra levels in T2D have yet to be identified. Islet amyloid deposits are protein aggregates formed by a small protein named islet amyloid polypeptide that is produced in the pancreatic ß-cells. Amyloid deposits are toxic to ß-cells and contribute to progressive ß-cell loss in T2D and transplanted islets in T1D patients. Growing evidence suggests that islet amyloid contributes to islet inflammation.In these studies, we will use pancreatic islets (cluster of cells containing ß-cells) from cadaveric human pancreatic donors and mouse models of human islet amyloid formation, to investigate the molecular mechanisms by which amyloid formation destroys ß-cells. We will use various molecular techniques to identify the role of IL-1Ra and IL-1ß signaling in amyloid-induced ß-cell toxicity. Through these studies, we hope to find new therapeutic approaches to preserve insulin producing ß-cells in patients with T2D and prolong survival of islet grafts in patients with T1D and thereby improve the lives of diabetic patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hui, Queenie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~